Hypermethylation of genes for diagnosis and risk stratification of prostate cancer

Donkena Krishna Vanaja, Mathias Ehrich, Dirk Van Den Boom, John C. Cheville, R. Jeffrey Karnes, Donald J. Tindall, Charles R. Cantor, Charles Y.F. Young

Research output: Contribution to journalArticlepeer-review

107 Scopus citations


To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

Original languageEnglish (US)
Pages (from-to)549-560
Number of pages12
JournalCancer Investigation
Issue number5
StatePublished - Jun 2009


  • CpG site methylation
  • Mass spectrometry assay
  • Molecular markers
  • Prostate cancer
  • Recurrence prediction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hypermethylation of genes for diagnosis and risk stratification of prostate cancer'. Together they form a unique fingerprint.

Cite this